The DTWD2 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the extensively characterized HEK293T human embryonic kidney cell line, engineered to disrupt the endogenous DTWD2 gene. This loss-of-function model enables systematic investigation of mitochondrial tRNA modification and translational control. By targeting DTWD2, researchers can dissect the molecular consequences of impaired mitochondrial gene expression in a robust, highly transfectable host background, providing a versatile platform for functional genomics and mitochondrial biology studies.
HEK293T cells are a widely used derivative of the HEK293 line, originally established by transformation of human embryonic kidney cells with sheared adenovirus 5 DNA. They constitutively express the SV40 large T antigen, which promotes episomal replication of plasmids harboring the SV40 origin of replication, resulting in exceptional transfectability and high recombinant protein yields. These characteristics have made HEK293T a preferred host for protein overexpression, viral packaging, and signaling pathway analysis. Their metabolic flexibility and proven utility in mitochondrial research further enhance their suitability for studying the impact of DTWD2 disruption on cellular energetics.
DTWD2 encodes a DTW domain-containing protein that is predicted to function as a mitochondrial tRNA-modifying enzyme. It catalyzes the addition of specific chemical groups to mitochondrial tRNAs, such as mt-tRNAUUR and mt-tRNALys, ensuring proper codon-anticodon pairing and efficient translation of mitochondrial-encoded subunits of respiratory chain complexes I, III, IV, and V. DTWD2 is regulated by transcriptional coactivators of mitochondrial biogenesis, including PGC-1?? and NRF1, which couple its expression to cellular energy status. The protein physically interacts with tRNA modification machineries, notably TRMT5 and TRMT10C, as well as the mitochondrial RNA polymerase POLRMT and mitochondrial ribosomal proteins, positioning it at the nexus of mitochondrial gene expression and respiratory function.
In the HEK293T context, loss of DTWD2 is expected to compromise mitochondrial translation fidelity, leading to defective oxidative phosphorylation and altered cellular metabolism. Because HEK293T cells rely on both glycolytic and oxidative energy production, the knockout can be used to dissect the adaptive metabolic responses to mitochondrial dysfunction. This model is particularly valuable for assessing how impaired tRNA modification impacts respiratory chain assembly, ATP synthesis, and cell growth, and may provide insights into mitochondrial disorders with suspected defects in tRNA modification pathways. The polyclonal nature of the population ensures that functional consequences can be evaluated without clonal selection artifacts.
This knockout model supports a broad range of experimental strategies, including Western blotting of mitochondrial respiratory chain subunits, Seahorse metabolic flux analysis of oxygen consumption and extracellular acidification, and high-resolution respirometry to quantify respiratory complex activities. It also facilitates mass spectrometry-based analysis of mitochondrial tRNA modifications, RT-qPCR profiling of mitochondrial-encoded transcripts, immunofluorescence for mitochondrial morphology, and cell viability and ATP assays. These tools enable detailed interrogation of the role of DTWD2 in tRNA biology and mitochondrial homeostasis. For further information, please contact Ascent Research.
